Study to Determine the Effects of Testosterone Replacement Therapy in Aging Men With Androgen Deficiency
This study has been completed.
Sponsor:
Urological Sciences Research Foundation
Collaborators:
Solvay Pharmaceuticals
Watson Pharmaceuticals
Information provided by:
Urological Sciences Research Foundation
ClinicalTrials.gov Identifier:
NCT00161304
First received: September 8, 2005
Last updated: September 11, 2005
Last verified: November 2004
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The T-001 study is a placebo-controlled investigation of the effects of injectable testosterone replacement therapy on prostate tissues of aging men with low testosterone levels. The primary objectives of the study are to measure the changes in tissue hormones and other biomarkers in the prostate tissue specimens.
| Condition | Intervention | Phase |
|---|---|---|
|
Men With Low Testosterone Levels |
Drug: Testosterone Enanthate |
Phase 2 Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment |
| Official Title: | Effects of Testosterone Administration on Tissues of Men With A.D.A.M. (Androgen Deficiency of Aging Men) |
Resource links provided by NLM:
Drug Information available for:
Testosterone propionate
Methyltestosterone
Testosterone cypionate
Testosterone
Testosterone enanthate
U.S. FDA Resources
Further study details as provided by Urological Sciences Research Foundation:
Eligibility| Ages Eligible for Study: | 50 Years and older |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:Inclusion Criteria
- Male aged 50-80 years of age, ambulatory, and in good general physical and mental health.
- Clinical diagnosis of hypogonadism defined as a serum testosterone level less than 300 ng/dl on a morning serum sample during the screening period.
- Answering yes to question 1 or 7 or to any three questions total on the Morley index at baseline.
- PSA <10 ng/ml
- Subject is able to give informed consent.
Exclusion Criteria
- Failure to meet the criteria for inclusion
- History of allergy to testosterone or any components of the delivery system.
- Significant abnormalities on pre-study clinical examination or laboratory measurements.
- Treatment with any investigational drug during the previous month.
- Drug or alcohol abuse or dependence.
- Concurrent use of testosterone and or any hormonal therapy, including health food supplements and herbal products, that could alter serum testosterone levels or affect the prostate (e.g. gonadotropic releasing hormone agonists, testosterone antagonists, anabolic steroids, DHEA, androstenedione, PC-SPES, chrysin and tribulus terrestris,). Use of alpha-reductase inhibitors or prostate phytotherapy within the past 3 months.
- Use of antidepressant medications, oral glucocorticoids, or opioids.
- PSA > 10 ng/ml and/or prostate biopsy positive for cancer at screening. Any patient in whom there is a suspicion of prostate cancer must undergo appropriate testing to rule out cancer prior to entry into the study.
- IPSS score 20.
- History of malignancy of any type (except basal cell carcinoma).
- Patients with uncontrolled diabetes.
- Patients with known or suspected bleeding disorder. Concurrent use of Coumadin and other anticoagulants at the time of biopsy or if discontinuation of such therapy prior to biopsy poses a risk to the patient.
- Inability of the patient to provide written informed consent for any reason, including legal incompetence, language or comprehension difficulty, and psychological, psychiatric or emotional factors.
- Inability of the patient to have transrectal ultrasonography with biopsy (for any reason).
- A history of any illness or condition that, in the opinion of the investigator, might confound the results of the study or pose additional risk to the patient.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00161304
Locations
| United States, California | |
| Urological Sciences Research Foundation | |
| Culver City, California, United States, 90232 | |
Sponsors and Collaborators
Urological Sciences Research Foundation
Solvay Pharmaceuticals
Watson Pharmaceuticals
Investigators
| Principal Investigator: | Leonard S Marks, M.D. | Urological Sciences Research Foundation |
More Information
Additional Information:
Related Info 
No publications provided by Urological Sciences Research Foundation
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| ClinicalTrials.gov Identifier: | NCT00161304 History of Changes |
| Other Study ID Numbers: | T-001 |
| Study First Received: | September 8, 2005 |
| Last Updated: | September 11, 2005 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Testosterone Testosterone enanthate Testosterone undecanoate Testosterone 17 beta-cypionate Androgens Methyltestosterone Hormones |
Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Pharmacologic Actions Antineoplastic Agents, Hormonal Antineoplastic Agents Therapeutic Uses Anabolic Agents |
ClinicalTrials.gov processed this record on May 19, 2013